{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-019332","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2022-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.404074+00:00","generated_at":"2026-06-23T05:09:15.892424+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Surrozen enters $12.5M upfront license deal with Boehringer Ingelheim for Fzd4 bispecific antibodies","bullets":["Upfront payment of $12.5 million; eligible for up to $586.5M in development, regulatory, and commercial milestones.","Royalties on net sales range from mid-single digit to low-double digit, subject to standard reductions.","Boehringer Ingelheim leads development and commercialization of SZN-413 and other Fzd4 bispecifics for retinal diseases.","5-year exclusivity: Surrozen cannot develop Fzd4 bispecifics for eye diseases; BI restricted to eye diseases.","Collaborative research period of one year (BI may extend 6 months) after which BI selects lead and back-up candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-019332","json":"https://secwatch.observer/filing/0000950170-22-019332.json","markdown":"https://secwatch.observer/filing/0000950170-22-019332.md","text":"https://secwatch.observer/filing/0000950170-22-019332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022019332/0000950170-22-019332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022019332/srzn-20220930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:09:15.892424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}